FDA Approves GEMCITABINE — Sagent Pharmaceuticals

# FDA Approves Sagent Pharmaceuticals' Generic Gemcitabine Injection Sagent Pharmaceuticals has received FDA approval for its generic gemcitabine hydrochloride intravenous formulation (ANDA209077), potentially expanding access to the chemotherapy treatment while increasing competitive pricing pressure in the oncology injectable market. The approval could enable Sagent to capture market share in the gemcitabine segment, which treats multiple cancer types including pancreatic, breast, and lung cancers.